# A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/a-phase-iib-dose-ranging-study-of-the-oral-jak-inhibitor-tofacitinib-cp-690-550/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Joel M. Kremer,Stanley Cohen,Bethanie Wilkinson,Carol A. Connell,Jonathan French,Juan J. Gómez‐Reino,David Gruben,Keith S. Kanik,Sriram Krishnaswami,Virginia Pascual‐Ramos,Gene V. Wallenstein,Samuel H. Zwillich |
| Citations | 347 |
| DOI | 10.1002/art.33419 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | http://hdl.handle.net/20.500.11940/4707 |
| OpenAlex ID | https://openalex.org/W2038992287 |
| PMID | 22006202 |
| Type | article |
| Year | 2011 |

## Paper authors

- [David Gruben](https://scholariq.org/researchers/david-gruben/)

## Paper primary topic

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)

## Paper topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.